Abstract:We propose a backward tracking model for measuring knowledge transfer in the whole translational research spectrum. Using the drugs-patents-papers-grants backward linkages, we try to figure out the funding-science-technology-innovation translational pattern and ponder some policy implications on e.g., which priority areas and knowledge convergence level are more likely to generate new drugs. The drug-patent linkage data was accessed through the USFDA Orange Book, covering a drug's active ingredient, formulation, or methods of use for approved indications. It will take about 10 years from the application of earliest patent to the approval of the new drug. Also such high-value patents in FDA Orange Book tend to cite scientific knowledge published on average 10-15 years ago. The technology linkage of new drugs was relatively stable while the science linkage of technology inventions increased rapidly. Among the scientific papers cited by drug patents, private-institution originated papers are only a quarter of the public. By linking theses scientific papers with funding sources, we found a large majority (90%) are public-funded and only a very small part are private-funded or public-private joint-funded. Our study also indicates the importance of research on such fields as pharmacology, chemistry (including medicinal chemistry, biochemistry, and organic chemistry), molecular biology, neurosciences, and immunology on new drugs innovation. There is no obvious relationship between "basicness" and linkages to the resulting patents' impact and to drugs innovation. A balanced basic research and applied research maybe essential for fostering drug innovation because it is a complete chain translating from basic discovery to clinical evidence then to clinical practice. In order to achieve successful pharmaceutical innovation, rather than focusing on only technology, convergence with science at moderate levels (maybe 1/3) is suggested. (C) 2018 The Authors. Published by Elsevier Ltd.

Knowledge transfers from federally supported R&D

Knowledge Spillovers and Corporate Investment in Scientific Research

Public policy measures in support of knowledge transfer activities: a review of academic literature

A Different Certification Effect of the Small Business Innovation Research (SBIR) Program

Early firm engagement, government research funding, and the privatization of public knowledge

Does Public Funding of University R&D Influence High-Tech Entrepreneurship?

The knowledge spillover of innovation

Influencing Factors and Case Study of Knowledge Transfer in Inter-firm Networks

Knowledge Spillovers Within China’s System of Research Institutes

Knowledge spillovers or R&D collaboration? Understanding the role of external knowledge for firm innovation

Public research and the innovation performance of new technology based firms

Technology Stocks: A Study on the Characteristics That Help Transfer Public Research to Industry

Technology Transfer from National/federal Labs and Public Research Institutes: Managerial and Policy Implications

Measuring the Knowledge Translation and Convergence in Pharmaceutical Innovation by Funding-Science-technology-innovation Linkages Analysis

The effects of R&D subsidies and network embeddedness on R&D output: evidence from the German biotech industry

The Role of Public External Knowledge for Firm Innovativeness

R&D and Technology Transfer: Firm-Level Evidence from Chinese Industry

University–Industry Technology Transfer: Empirical Findings from Chinese Industrial Firms

The impact on innovation performance of different sources of knowledge: Evidence from the UK Community Innovation Survey

Critical factors for success in university–industry research projects